Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TAS 102”

110 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 110 results

Large-scale testing (Phase 3)Ended earlyNCT05328908
What this trial is testing

Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Who this might be right for
Colorectal Neoplasms
Bristol-Myers Squibb 770
Large-scale testing (Phase 3)Looking for participantsNCT06614192
What this trial is testing

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
AbbVie 460
Testing effectiveness (Phase 2)Looking for participantsNCT05343013
What this trial is testing

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Who this might be right for
Colorectal Cancer
M.D. Anderson Cancer Center 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04294264
What this trial is testing

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Who this might be right for
Metastatic Colorectal CarcinomaRecurrent Colon CarcinomaRefractory Colorectal Carcinoma+3 more
Rutgers, The State University of New Jersey 50
Early research (Phase 1)Study completedNCT02301117
What this trial is testing

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Who this might be right for
Advanced Solid Tumors
Taiho Oncology, Inc. 43
Testing effectiveness (Phase 2)Study completedNCT04923529
What this trial is testing

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Who this might be right for
Pancreas Cancer
The University of Hong Kong 28
Testing effectiveness (Phase 2)UnknownNCT06039202
What this trial is testing

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Holy Stone Healthcare Co., Ltd 100
Testing effectiveness (Phase 2)Looking for participantsNCT06699836
What this trial is testing

Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC

Who this might be right for
Metastatic Colorectal Cancer (mCRC)
CytoDyn, Inc. 60
Testing effectiveness (Phase 2)UnknownNCT05314101
What this trial is testing

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Who this might be right for
ImmunotherapyColorectal Cancer
Fujian Cancer Hospital 25
Testing effectiveness (Phase 2)Study completedNCT03686488
What this trial is testing

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 23
Testing effectiveness (Phase 2)UnknownNCT03762161
What this trial is testing

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Who this might be right for
Bladder Cancer
Rahul Parikh 22
Testing effectiveness (Phase 2)Study completedNCT04097028
What this trial is testing

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+13 more
Roswell Park Cancer Institute 22
Testing effectiveness (Phase 2)Ended earlyNCT02921737
What this trial is testing

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

Who this might be right for
Pancreatic Cancer
University of Florida 7
Testing effectiveness (Phase 2)Looking for participantsNCT05965531
What this trial is testing

Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy

Who this might be right for
Rectal Cancer
Sun Yat-sen University 65
Not applicableStudy completedNCT06031376
What this trial is testing

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Who this might be right for
Metastatic Colorectal Adenocarcinoma
Hunan Cancer Hospital 106
Testing effectiveness (Phase 2)Study completedNCT04808791
What this trial is testing

ITTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastroesophageal Junction AdenocarcinomaAdvanced Gastric Carcinoma
AHS Cancer Control Alberta 7
Testing effectiveness (Phase 2)Looking for participantsNCT06242067
What this trial is testing

Second-line Treatment of Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Qilu Hospital of Shandong University 50
Not applicableUnknownNCT05993702
What this trial is testing

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

Who this might be right for
TAS 102RegorafenibFruquintinib+1 more
China Medical University, China 45
Not applicableEnrolling By InvitationNCT06936488
What this trial is testing

A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer

Who this might be right for
MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients
Huai'an First People's Hospital 35
Not applicableLooking for participantsNCT05991102
What this trial is testing

Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer

Who this might be right for
Refractory Metastatic Colorectal Cancer
Charite University, Berlin, Germany 12
Load More Results